Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer

Shannon Puhalla, Adam BrufskyUPMC Magee-Womens Cancer Program, University of Pittsburgh, Pittsburgh, Pennsylvania, USAAbstract: Taxane therapy is commonly used in the treatment of metastatic breast cancer. However, most patients will eventually become refractory to these agents. Ixabepilone is a new...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Shannon Puhalla, Adam Brufsky
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://doaj.org/article/4209a5255f9042edac6dae63e7d778f0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:4209a5255f9042edac6dae63e7d778f0
record_format dspace
spelling oai:doaj.org-article:4209a5255f9042edac6dae63e7d778f02021-12-02T02:16:02ZIxabepilone: a new chemotherapeutic option for refractory metastatic breast cancer1177-54751177-5491https://doaj.org/article/4209a5255f9042edac6dae63e7d778f02008-09-01T00:00:00Zhttp://www.dovepress.com/ixabepilone-a-new-chemotherapeutic-option-for-refractory-metastatic-br-a2300https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Shannon Puhalla, Adam BrufskyUPMC Magee-Womens Cancer Program, University of Pittsburgh, Pittsburgh, Pennsylvania, USAAbstract: Taxane therapy is commonly used in the treatment of metastatic breast cancer. However, most patients will eventually become refractory to these agents. Ixabepilone is a newly approved chemotherapeutic agent for the treatment of metastatic breast cancer. Although it targets microtubules similarly to docetaxel and paclitaxel, ixabepilone has activity in patients that are refractory to taxanes. This review summarizes the pharmacology of ixapebilone and clinical trials with the drug both as a single agent and in combination. Data were obtained using searches of PubMed and abstracts of the annual meetings of the American Society of Clinical Oncology and the San Antonio Breast Cancer Symposium from 1995 to 2008. Ixapebilone is a semi-synthetic analog of epothilone B that acts to induce apoptosis of cancer cells via the stabilization of microtubules. Phase I clinical trials have employed various dosing schedules ranging from daily to weekly to 3-weekly. Dose-limiting toxicites included neuropathy and neutropenia. Responses were seen in a variety of tumor types. Phase II studies verified activity in taxane-refractory metastatic breast cancer. The FDA has approved ixabepilone for use as monotherapy and in combination with capecitabine for the treatment of metastatic breast cancer. Ixabepilone is an efficacious option for patients with refractory metastatic breast cancer. The safety profile is similar to that of taxanes, with neuropathy and neutropenia being dose-limiting. Studies are ongoing with the use of both iv and oral formulations and in combination with other chemotherapeutic and biologic agents.Keywords: ixabepilone, epothilone, metastatic breast cancer, taxane-refractory Shannon PuhallaAdam BrufskyDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 3, Pp 505-515 (2008)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Shannon Puhalla
Adam Brufsky
Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
description Shannon Puhalla, Adam BrufskyUPMC Magee-Womens Cancer Program, University of Pittsburgh, Pittsburgh, Pennsylvania, USAAbstract: Taxane therapy is commonly used in the treatment of metastatic breast cancer. However, most patients will eventually become refractory to these agents. Ixabepilone is a newly approved chemotherapeutic agent for the treatment of metastatic breast cancer. Although it targets microtubules similarly to docetaxel and paclitaxel, ixabepilone has activity in patients that are refractory to taxanes. This review summarizes the pharmacology of ixapebilone and clinical trials with the drug both as a single agent and in combination. Data were obtained using searches of PubMed and abstracts of the annual meetings of the American Society of Clinical Oncology and the San Antonio Breast Cancer Symposium from 1995 to 2008. Ixapebilone is a semi-synthetic analog of epothilone B that acts to induce apoptosis of cancer cells via the stabilization of microtubules. Phase I clinical trials have employed various dosing schedules ranging from daily to weekly to 3-weekly. Dose-limiting toxicites included neuropathy and neutropenia. Responses were seen in a variety of tumor types. Phase II studies verified activity in taxane-refractory metastatic breast cancer. The FDA has approved ixabepilone for use as monotherapy and in combination with capecitabine for the treatment of metastatic breast cancer. Ixabepilone is an efficacious option for patients with refractory metastatic breast cancer. The safety profile is similar to that of taxanes, with neuropathy and neutropenia being dose-limiting. Studies are ongoing with the use of both iv and oral formulations and in combination with other chemotherapeutic and biologic agents.Keywords: ixabepilone, epothilone, metastatic breast cancer, taxane-refractory
format article
author Shannon Puhalla
Adam Brufsky
author_facet Shannon Puhalla
Adam Brufsky
author_sort Shannon Puhalla
title Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
title_short Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
title_full Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
title_fullStr Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
title_full_unstemmed Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
title_sort ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/4209a5255f9042edac6dae63e7d778f0
work_keys_str_mv AT shannonpuhalla ixabepiloneanewchemotherapeuticoptionforrefractorymetastaticbreastcancer
AT adambrufsky ixabepiloneanewchemotherapeuticoptionforrefractorymetastaticbreastcancer
_version_ 1718402588146139136